WEBSITE BSE:0 NSE: Inc. Year: 2010 Industry: Medical Equipment/Supplies/Accessories
Last updated: 15:31
Incorporated on July 2010, Yash Optics & Lens Limited is a public technology-driven company specializing in the manufacturing of optical lenses. Over the last 24 years, Yash Optics & Lens has emerged as a leading provider of hi-tech digital vision healthcare solutions across the Indian subcontinent. Company has carved out a niche for its expertise in manufacturing optical lenses and stands at the forefront of delivering these solutions to people of India. With a focus on innovation and quality, Yash Optics & Lens is committed to providing produ...Read More
Incorporated on July 2010, Yash Optics & Lens Limited is a public technology-driven company specializing in the manufacturing of optical lenses. Over the last 24 years, Yash Optics & Lens has emerged as a leading provider of hi-tech digital vision healthcare solutions across the Indian subcontinent. Company has carved out a niche for its expertise in manufacturing optical lenses and stands at the forefront of delivering these solutions to people of India. With a focus on innovation and quality, Yash Optics & Lens is committed to providing products that meet the highest standards of the optical industry without compromising on the commitment. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹261 Cr.
Stock P/E 27.3
P/B 2.9
Current Price ₹105.6
Book Value ₹ 36.5
Face Value 10
52W High ₹153.5
Dividend Yield 0%
52W Low ₹ 72.6
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 15 | 30 | 40 | 41 | 43 | |
| Other Income | 0 | 0 | 0 | 0 | 3 | |
| Total Income | 15 | 30 | 40 | 41 | 46 | |
| Total Expenditure | 13 | 20 | 27 | 27 | 31 | |
| Operating Profit | 2 | 10 | 13 | 15 | 15 | |
| Interest | 1 | 1 | 1 | 2 | 1 | |
| Depreciation | 0 | 1 | 1 | 1 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 9 | 11 | 12 | 13 | |
| Provision for Tax | 0 | 2 | 3 | 3 | 3 | |
| Profit After Tax | 1 | 7 | 8 | 9 | 10 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 1 | 7 | 8 | 9 | 10 | |
| Adjusted Earnings Per Share | 0.6 | 3.8 | 4.5 | 5 | 3.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 5% | 13% | 0% | 0% |
| Operating Profit CAGR | 0% | 14% | 0% | 0% |
| PAT CAGR | 11% | 13% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 38% | NA% | NA% | NA% |
| ROE Average | 16% | 35% | 44% | 44% |
| ROCE Average | 18% | 34% | 40% | 40% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | 4 | 11 | 19 | 30 | 90 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 6 | 4 | 11 | 17 | 12 |
| Other Non-Current Liabilities | 0 | 0 | 1 | 1 | 1 |
| Total Current Liabilities | 2 | 9 | 3 | 13 | 8 |
| Total Liabilities | 12 | 24 | 34 | 61 | 112 |
| Fixed Assets | 0 | 4 | 8 | 19 | 30 |
| Other Non-Current Assets | 0 | 0 | 0 | 8 | 12 |
| Total Current Assets | 12 | 20 | 26 | 33 | 70 |
| Total Assets | 12 | 24 | 34 | 61 | 112 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 0 | 1 | 1 |
| Cash Flow from Operating Activities | -0 | 8 | -12 | -12 | 6 |
| Cash Flow from Investing Activities | -0 | -5 | -8 | -19 | -37 |
| Cash Flow from Financing Activities | 0 | -2 | 10 | 31 | 31 |
| Net Cash Inflow / Outflow | 0 | 0 | -11 | 0 | -0 |
| Closing Cash & Cash Equivalent | 1 | 1 | -11 | 1 | 1 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.6 | 3.85 | 4.53 | 4.96 | 3.87 |
| CEPS(Rs) | 0.65 | 4.19 | 4.93 | 5.44 | 4.36 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 2.41 | 6.24 | 10.75 | 16.39 | 36.49 |
| Core EBITDA Margin(%) | 13.74 | 34.35 | 31.42 | 35.52 | 29.12 |
| EBIT Margin(%) | 13.3 | 32.66 | 29.89 | 33.63 | 32.9 |
| Pre Tax Margin(%) | 9.93 | 30.79 | 27.33 | 29.48 | 30.06 |
| PAT Margin (%) | 7.11 | 22.91 | 20.22 | 21.95 | 22.19 |
| Cash Profit Margin (%) | 7.67 | 24.97 | 21.97 | 24.07 | 24.98 |
| ROA(%) | 8.78 | 37.3 | 27.45 | 19.07 | 11.11 |
| ROE(%) | 24.92 | 89.02 | 53.35 | 36.92 | 15.95 |
| ROCE(%) | 19.68 | 77.15 | 52.78 | 32.53 | 17.76 |
| Receivable days | 99.66 | 72.61 | 77.5 | 92.76 | 115.71 |
| Inventory Days | 152.02 | 102.7 | 119.9 | 158.4 | 178.05 |
| Payable days | 57.45 | 163.99 | 124.87 | 94.47 | 108.47 |
| PER(x) | 0 | 0 | 0 | 0 | 20.72 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 2.2 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.33 | 0.09 | 0.26 | 1.04 | 4.2 |
| EV/Core EBITDA(x) | 2.4 | 0.27 | 0.82 | 2.9 | 11.77 |
| Net Sales Growth(%) | 0 | 98.84 | 33.45 | 3.55 | 5.1 |
| EBIT Growth(%) | 0 | 388.08 | 22.14 | 16.48 | 2.83 |
| PAT Growth(%) | 0 | 541.21 | 17.77 | 12.39 | 6.27 |
| EPS Growth(%) | 0 | 541.21 | 17.77 | 9.34 | -21.89 |
| Debt/Equity(x) | 1.37 | 0.36 | 0.57 | 0.85 | 0.16 |
| Current Ratio(x) | 6.49 | 2.19 | 7.48 | 2.49 | 8.5 |
| Quick Ratio(x) | 3.09 | 1.03 | 2.99 | 0.98 | 5.83 |
| Interest Cover(x) | 3.95 | 17.49 | 11.68 | 8.11 | 11.59 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.07 |
| # | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|
| Promoter | 71.63 | 73.06 | 73.18 |
| FII | 1.71 | 0.75 | 0 |
| DII | 0.98 | 0.96 | 0.01 |
| Public | 25.69 | 25.23 | 26.81 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|
| Promoter | 1.77 | 1.81 | 1.81 |
| FII | 0.04 | 0.02 | 0 |
| DII | 0.02 | 0.02 | 0 |
| Public | 0.64 | 0.62 | 0.66 |
| Others | 0 | 0 | 0 |
| Total | 2.48 | 2.48 | 2.48 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
